WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology...
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for...
FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that...
Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - September...
– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need...
MESA, ARIZONA / ACCESS Newswire / September 18, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a leader in AI-powered...
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prussia,...
FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that...
With high-value assets including a LeBron James 2016 NBA Finals game worn jersey and rare Tom Brady 1/1 card, Infinite...
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope®...
Pilot studies have shown encouraging results that are supporting the company’s pre-IND enabling development, marking a critical step toward clinical...
"Company anticipates achieving debt-free status by year-end, reinforcing commitment to AI-driven healthcare technologies" MESA, ARIZONA / ACCESS Newswire / September...
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that...
Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology...
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany...
MESA, ARIZONA / ACCESS Newswire / September 4, 2025 / Medical Care Technologies Inc. (OTC PINK: MDCE) is proud to...
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf...
HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical...
Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-7625th cohort patients now being treated in...
Ramat Gan, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company...